Were the reported BIOF share sales made under a Rule 10b5-1 trading plan?

No. The filing indicates no Rule 10b5-1 trading plan for these transactions; they are simply described as sales in open-market or private transactions.

Blue Biofuels director sells 1M shares at $0.09–0.10

Q: What insider transaction did BLUE BIOFUELS (BIOF) disclose for Chris J. Kneppers?

The filing reports that director Chris J. Kneppers sold 1,000,000 shares of BLUE BIOFUELS Common Stock in three transactions between September 1 and September 3, 2026, described as sales in open-market or private transactions.

Q: At what prices were the BIOF shares sold in this Form 4 filing?

The reported sales were executed at $0.09 per share on September 1 and 2, 2026, and at $0.10 per share on September 3, 2026, for BLUE BIOFUELS Common Stock.

Q: How many BIOF shares did Chris J. Kneppers sell on each date?

Chris J. Kneppers sold 200,000 shares on September 1, 2026, 700,000 shares on September 2, 2026, and 100,000 shares on September 3, 2026, for a total of 1,000,000 shares of BLUE BIOFUELS Common Stock.

Q: Does the Form 4 indicate how many BIOF shares Chris J. Kneppers still holds?

A remark in the filing states that 19,472,677 shares are held jointly with Angela Kneppers. This indicates a large joint holding associated with Chris J. Kneppers in BLUE BIOFUELS stock.

Q: What is Chris J. Kneppers’s role at BLUE BIOFUELS (BIOF)?

The Form 4 identifies Chris J. Kneppers as a director of BLUE BIOFUELS, INC., making these reported sales director-level insider transactions in the company’s Common Stock.

A BLUE BIOFUELS director sold 1,000,000 BIOF shares over three days while continuing to jointly hold 19,472,677 shares.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

BLUE BIOFUELS, INC. (BIOF) director Chris J. Kneppers reported selling a total of 1,000,000 shares of Common Stock in three open-market or private transactions from September 1 to September 3, 2026, at prices between $0.09 and $0.10 per share. A remark states that 19,472,677 shares are held jointly with Angela Kneppers, indicating a substantial remaining joint position. No transactions are reported as made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Seller: 1,000,000 shares

Net Sell 3 txns

Insider Kneppers Chris J

Role Director

Sold 1,000,000 shs ($91K)

Type	Security	Shares	Price	Value
Sale	Common Stock	100,000	$0.10	$10K
Sale	Common Stock	700,000	$0.09	$63K
Sale	Common Stock	200,000	$0.09	$18K

Holdings After Transaction: Common Stock — 20,472,677 shares (Direct)

Key Figures

Total shares sold: 1,000,000 shares Shares sold on September 1, 2026: 200,000 shares Shares sold on September 2, 2026: 700,000 shares +3 more

6 metrics

Total shares sold 1,000,000 shares Aggregate insider sales by director Chris J. Kneppers from September 1–3, 2026

Shares sold on September 1, 2026 200,000 shares Sale of BLUE BIOFUELS Common Stock at $0.09 per share

Shares sold on September 2, 2026 700,000 shares Sale of BLUE BIOFUELS Common Stock at $0.09 per share

Shares sold on September 3, 2026 100,000 shares Sale of BLUE BIOFUELS Common Stock at $0.10 per share

Sale price range $0.09–$0.10 per share Per-share prices for reported BLUE BIOFUELS insider sales

Jointly held shares 19,472,677 shares Shares reported as held jointly with Angela Kneppers

Key Terms

open market or private transaction, Common Stock, jointly

3 terms

open market or private transaction financial

"Sale in open market or private transaction"

Common Stock financial

"Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

jointly financial

"19,472,677 shares are held jointly with Angela Kneppers"

FAQ

What insider transaction did BLUE BIOFUELS (BIOF) disclose for Chris J. Kneppers?

The filing reports that director Chris J. Kneppers sold 1,000,000 shares of BLUE BIOFUELS Common Stock in three transactions between September 1 and September 3, 2026, described as sales in open-market or private transactions.

At what prices were the BIOF shares sold in this Form 4 filing?

The reported sales were executed at $0.09 per share on September 1 and 2, 2026, and at $0.10 per share on September 3, 2026, for BLUE BIOFUELS Common Stock.

How many BIOF shares did Chris J. Kneppers sell on each date?

Chris J. Kneppers sold 200,000 shares on September 1, 2026, 700,000 shares on September 2, 2026, and 100,000 shares on September 3, 2026, for a total of 1,000,000 shares of BLUE BIOFUELS Common Stock.

Does the Form 4 indicate how many BIOF shares Chris J. Kneppers still holds?

A remark in the filing states that 19,472,677 shares are held jointly with Angela Kneppers. This indicates a large joint holding associated with Chris J. Kneppers in BLUE BIOFUELS stock.

What is Chris J. Kneppers’s role at BLUE BIOFUELS (BIOF)?

The Form 4 identifies Chris J. Kneppers as a director of BLUE BIOFUELS, INC., making these reported sales director-level insider transactions in the company’s Common Stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/03/2026 - 07:09 PM Accepted by SEC EDGAR 09/03/2026 - 07:08 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kneppers Chris J

(Last)

(First)

(Middle)

8 BETHPAGE DRIVE

(Street)

SKILLMAN,

NEW JERSEY

08558

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BLUE BIOFUELS, INC. [ BIOF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	09/01/2026		S		200,000	D	$0.09	21,272,677	D
Common Stock	09/02/2026		S		700,000	D	$0.09	20,572,677	D
Common Stock	09/03/2026		S		100,000	D	$0.1	20,472,677	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

Remarks:

19,472,677 shares are held jointly with Angela Kneppers.

	/s/ Chris Kneppers	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR